Immunogenicity, Safety, and Persistence Induced by Triple- and Standard-Strength 4-Dose Hepatitis B Vaccination Regimens in Patients Receiving Hemodialysis - Summary - MDSpire

Immunogenicity, Safety, and Persistence Induced by Triple- and Standard-Strength 4-Dose Hepatitis B Vaccination Regimens in Patients Receiving Hemodialysis

  • By

  • Tian Yao

  • Yandi Li

  • Yidan Zhang

  • Yangle Sun

  • Yana Guo

  • Jianmin Wang

  • Xiaohui Song

  • Wei Zhang

  • Baozhu Wei

  • Jingen Bai

  • Hui Wang

  • Weimin Yu

  • Huiyuan Wang

  • Lu Jiao

  • Yinqiang Diao

  • Liming Liu

  • Shuaishuai Shi

  • Jie Yang

  • Xiaojun Ren

  • Wenyuan Liu

  • Jingai Fang

  • Xiaofeng Liang

  • Suping Wang

  • Yongliang Feng

  • October 8, 2024

  • 0 min

Share

Objective:

To enhance the immunogenicity and persistence of hepatitis B vaccination in hemodialysis patients through high-dose and prolonged vaccination schedules.

Key Findings:
  • The antibody response peaked at month 7, with response rates decreasing over time across all groups.
  • The duration of protective antibody levels was significantly longer in the IM60 × 4 group (29.2 months) compared to IM20 × 3 group (21.0 months).
  • All adverse reactions reported were mild.
Interpretation:

Triple-strength 4-dose hepatitis B vaccination regimens significantly enhance immunogenicity and prolong the duration of protective antibodies in hemodialysis patients compared to standard regimens.

Limitations:
  • The study was conducted in a single region (Shanxi province, China), which may limit generalizability.
  • The follow-up period, while extensive, may not capture long-term effects beyond 30 months.
Conclusion:

The triple-strength 4-dose hepatitis B vaccination regimen is more effective in maintaining protective antibody levels in hemodialysis patients, suggesting a need for revised vaccination strategies.

Original Source(s)

Related Content